AZNAstraZenecaSigning up patients
Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 60 (planned)
- Started
- Apr 1, 2026
- Main results expected
- May 30, 2029
- Fully finished
- May 30, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
PFS (Progression-Free Survival)
Measured over: Assessed from date of first dose to progression (up to a maximum of approximately 2 years)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07295821 · record last updated 2026-10-28 · checked 2026-11-09 15:47 UTC